Combined miR-486 and GP88 (Progranulin) Serum Levels Are Suggested as Supportive Biomarkers for Therapy Decision in Elderly Prostate Cancer Patients

Our study aimed to assess the applicability of miR-486 in combination with soluble GP88 protein as a diagnostic and/or predictive biomarker for prostate cancer (PCa) patients. miR-486 and GP88 levels in serum samples from 136 patients undergoing MRI-guided biopsy of the prostate were assessed by qRT...

Descripción completa

Detalles Bibliográficos
Autores principales: Fichte, Alexander, Neumann, Angela, Weigelt, Katrin, Guzman, Juan, Jansen, Thilo, Keinert, Julia, Serrero, Ginette, Yue, Binbin, Stöhr, Robert, Greither, Thomas, Hartmann, Arndt, Wullich, Bernd, Taubert, Helge, Wach, Sven, Lieb, Verena
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9143270/
https://www.ncbi.nlm.nih.gov/pubmed/35629399
http://dx.doi.org/10.3390/life12050732

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9143270/
https://www.ncbi.nlm.nih.gov/pubmed/35629399
http://dx.doi.org/10.3390/life12050732

Ejemplares similares